Compare Eastern Bankshares Inc. Common Stock (EBC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eastern Bankshares Inc. Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Eastern Bankshares Inc. Common Stock trades at $20.77 (market cap $4.79B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Eastern Bankshares Inc. Common Stock is far larger — about 4.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Eastern Bankshares Inc. Common Stock pays a 2.67% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eastern Bankshares Inc. Common Stock for 0 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EBC | MRVI | |
|---|---|---|
Market Cap | $4.79B | $972.90M |
Volume | 1,740,716 | 4,325,710 |
Sector | Financials | Health |
52-Week High | $23.65 | $9.00 |
52-Week Low | $16.73 | $2.83 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $5.07B | $1.08B |
Dividend Yield | 2.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eastern Bankshares (EBC) trades at $20.96, down 0.85% on the day, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.71, net income margin of 33.47%, and recent Q2 2026 EPS beat. Analyst consensus is bullish with a $25.60 price target. Recent news highlights institutional buying and upcoming Q3 2026 earnings.
The outlook is positive given solid profitability, attractive valuation, and analyst support. Key risks include integration challenges from recent acquisitions and interest rate sensitivity. Upside potential exists if earnings momentum continues, but investors should monitor net cash flow trends and competitive pressures.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eastern Bankshares Inc. Common Stock
Eastern Bankshares, Inc. is the holding company for Eastern Bank, a Massachusetts-based bank operating more than 125 branches across eastern Massachusetts, southern and coastal New Hampshire, and Rhode Island, offering consumer and business banking along with wealth management through its Cambridge Trust divisions.
Read more on EBC →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
